Resistant Gram-negative Bacteria
|
|
- Augusta Lucas
- 5 years ago
- Views:
Transcription
1 Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria superbugs because they have supergenes. One of the more recent resistant strains is referred to as NDM-1, or New Delhi metallo-betalactamase-1. But extended-spectrum betalactamase (ESBL)-producing Enterobacteriaceae and multidrug resistant Pseudomonas are even more common. 1,2 This article reviews gramnegative bacterial resistance and treatment options. It also describes methods to prevent health care-associated infections. Mechanisms for Resistance Bacterial resistance to antibiotics occurred soon after penicillin became widely used. 3 And resistance has increased since then. In 2004, U.S. resistance rates were just over 50% in ICU and about 30% in non-icu isolates for Pseudomonas aeruginosa. 1 Beta-lactam drugs, such as penicillins and cephalosporins, work in different ways to kill gram-negative bacteria. However, these bacteria have adapted and evolved to become resistant. Decreased permeability. Gram-negative bacteria have an outer membrane which is compromised during drug entry. Gram-negative bacteria resist antibiotics by decreasing the permeability of this membrane. This means that less drug crosses the membrane into the bacteria. 4 Gram-negative bacteria will also use a pump to remove any drugs that penetrate the membrane. 4 Enzyme production. Gram-negative Enterobacteriaceae like Klebsiella and Escherichia are evolving to combat antibiotics. They produce enzymes to break down the broadspectrum beta-lactams. They also produce enzymes to break down many antibiotics that have historically been used last-line. PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2011 Resistant Gram-negative Bacteria Extended-spectrum beta-lactamase-producing Enterobacteriaceae have been inactivating the extended spectrum beta-lactams like aztreonam (Azactam) and third-generation cephalosporins since the 1980 s. 4 These bacteria are also frequently resistant to aminoglycosides and quinolones. 4 Resistance rates exceed 10% in some areas. 2 The threat of these bacteria has increased the use of carbapenem drugs since they usually aren t affected by extended-spectrum beta-lactamases. But gram-negative bacteria evolved again. They began producing carbapenemases (carbapenemhydrolyzing beta-lactamase). The carbapenemases inactivate carbapenems (Primaxin, etc). 5 Carbapenemase-producing bacteria also resist extended spectrum betalactams, quinolones, and aminoglycosides. 4 This leaves very few treatment options for diseases frequently treated with carbapenems. These include diseases such as sepsis of unknown origin, hospital-acquired pneumonia, and bacterial meningitis. The most common of these enzymes is Klebsiella pneumoniae carbapenemase, or KPC. 4 These enzymes aren t limited to Klebsiella. They are also in E. coli and P. aeruginosa and are found throughout the U.S. and Canada. 4 NDM-1 (New Delhi metallo-beta-lactamase-1) is one of the latest identified carbapenemase-producing bacteria. NDM-1 infections have only been seen in the past few years. As of June 2011, there s been about 250 cases worldwide from 2008 to And only seven of these have been reported in the U.S. and Canada. 6,7 Genetic changes. In addition to the production of enzymes, gram-negative bacteria have undergone genetic mutations. 4 Some have developed resistant genes. The resistance genes are often found in plasmids. Plasmids are very easily transferred between bacteria and allow resistance to spread rapidly. 2,3 NDM-1 is an example of a gram-negative bacteria that has
2 undergone genetic mutation. 4 NDM-1 can also be transmitted by asymptomatic carriers. 4,7 This bacterial evolution and mutation have resulted in multi-drug resistance, which is a growing public health concern. Identifying Susceptible Patients All patients are susceptible to resistant organisms. However, certain patient populations are more likely to harbor resistant bacteria. Suspect resistance to extended-spectrum betalactams in the following groups. Patients with previous antibiotic use, especially long term use of broad-spectrum antibiotics. This is specifically a concern in patients who ve had recent use of third-generation cephalosporins (ceftriaxone, ceftazidime, etc) or quinolones. 2 Institutionalized patients have a higher risk of multi-drug resistance. This is especially seen in intensive care units. Keep in mind that patients in other areas of the hospital are also susceptible. Patients in long term care facilities and those transferring between institutions are also at risk. 2 Patients with indwelling devices, such as catheters and endotracheal tubes, are more likely to be colonized or infected with multi-drug resistant organisms. Suggest removal of these devices as soon as possible. 2 Patients who are immunocompromised or over 60 years should also be suspected of harboring resistant organisms. 2 Patients who ve recently traveled to India or Pakistan may be at higher risk for NDM-1. 5 There are also reports in Great Britain of resistance in patients who haven t traveled. 7 This is likely due to cross-contamination within the hospital. 5 The CDC recommends asking patients with carbapenem-resistant Enterobacteriaceae about travel to India or Pakistan within the past six months. 8 In the U.S., carbapenem-resistant isolates from patients who received medical treatment in India or Pakistan within the past six months should be sent to the state public health lab. These isolates will then be forwarded to the CDC for additional analysis. 8 It s important to be aware of your hospital s antibiogram and the sensitivity and resistance patterns in your area. Klebsiella pneumoniae carbapenemases may indicate susceptibility to imipenem or meropenem, but the minimum inhibitory concentration (MIC) may be higher (PL Detail-Document #270713: Page 2 of 5) than normal. 2 If you suspect this resistant organism in your area, suggest your lab use ertapenem (Invanz) to identify susceptibility. 2 Specifically request sensitivity testing to colistin and tigecycline if you suspect a carbapenemaseresistant gram-negative infection or if there s intermediate resistance or resistance to carbapenems. Treating Resistant Gram-negative Bacteria The beta-lactams work in a time-dependent manner. So it s important for the drug concentration to remain above the MIC. 2,3 You want to aim for a drug concentration two to four times above the MIC. 3 Consider a carbapenem or tigecycline (Tygacil) as empiric therapy for severe infections thought to be due to gram-negative bacteria. 2 These may be given in combination with an antipseudomonal or an agent that covers methicillin-resistant Staph aureus. 2 It s important to identify the appropriate antibiotic as quickly as possible. Culture and sensitivity results, plus local resistance patterns, should be taken into consideration when selecting therapy. Extended-spectrum beta-lactamase-producing bacteria can typically be treated with carbapenems, such as imipenem and meropenem, or piperacillin-tazobactam (Zosyn, Tazocin). 2,4 Reserve fosfomycin (Monurol) for urinary tract infections. Consider quinolones as a second-line option. 2 Carbapenemase-producing bacteria have limited treatment options. Polymyxins may be appropriate for most infections. 1 Aminoglycosides are sometimes used, but resistance rates are as high as 45% to 90%. 4 Quinolone resistance is above 90% and quinolones should be avoided. 4 Colistin (polymyxin E) has the greatest effectiveness against NDM-1 [Evidence level D; in vitro]. 9 Between 90% to 100% of isolates are susceptible. 4,9 The parenteral formulation is referred to as colistin methanesulfonate (Coly- Mycin M, colistimethate sodium, or CMS). 1,7,10 Even though this drug has been around for over 50 years, there isn t much reliable kinetic data or dosing information available. 7 In the U.S. and Canada, Coly-Mycin M is typically dosed at 2.5 to 5 mg/kg/day in two to four divided doses. Many institutions dose two or three times daily to achieve higher drug concentrations. Note that
3 (PL Detail-Document #270713: Page 3 of 5) some references use international units. To convert, 12,500 international units of colistin is equal to 1 mg. 10 Adjust the colistin dosage in patients with poor baseline renal function. Follow your institutionspecific protocol. Some institutions use the following adjustments to colistin dosing in patients with renal impairment: MDRD of 40 to 70 ml/min/1.73 m 2 or CrCl of 30 to 49 ml/min give 3.5 mg/kg/day in two divided doses; MDRD of 25 to 40 ml/min/1.73 m 2 or CrCl of 10 to 29 ml/min give 2.5 mg/kg/day in two divided doses; MDRD of 10 to 25 ml/min/1.73 m 2 or CrCl <10 ml/min give 1.5 mg/kg/day as one dose. (MDRD=Modification of Diet in Renal Disease; MDRD equation is used to estimate GFR.) Some clinicians use the adjusted body weight if the patient s actual weight is greater than 130% of their ideal body weight. Monitor renal function daily when patients are in the hospital and every three days if they re outpatient. Also monitor electrolytes. You may see reversible renal or neuro toxicity in patients getting colistin. 1,11 Once daily dosing may increase these toxicities, but this isn t conclusive. Therefore, once daily dosing should be used cautiously. 1,11 The other option for treating carbapenemaseproducing bacteria (including NDM-1) is tigecycline [Evidence level D; in vitro]. 9 But only about 55% to 65% of NDM-1 isolates are susceptible. 4,9 Tigecycline doesn t reach adequate concentrations in the bloodstream or urinary tract, so its use is limited. 2 The usual tigecycline dose is a 100 mg loading dose followed by 50 mg every 12 hours. Some experts suggest higher doses may be needed to treat resistant organisms. The standard length of treatment is five to 14 days. However, resistant organisms and severe infections usually require a longer course of treatment. Use a reduced dose in patients with severe hepatic impairment. 1 The optimal tigecycline dose and duration of use for treating resistant bacteria is not clearly defined. Studies are needed before combination therapy can be routinely recommended. 1,3 Preventing Health Care-associated Infections Being proactive is the key to preventing the spread of resistant bacteria and decreasing the number of health care-associated infections. Hand washing is a simple step that can decrease the spread of infection. Wash your hands for at least ten to 20 seconds. An alcoholbased hand rub is appropriate for most organisms except Clostridium difficile. Use soap and water when C. diff is suspected or if hands are visibly soiled. 12,13 Use personal protective equipment when appropriate. This includes gloves, gown, and face mask or respirator. Remove your gloves and gown before leaving a patient s room and immediately wash your hands after leaving and before touching anything. 12,13 Cross-contamination can be prevented by keeping patient care equipment such as thermometers and pulse oximeters dedicated to a specific patient. Items not appropriate for singleuse should be cleaned and disinfected before use by another patient. 12,13 Isolate patients with resistant organisms or highly contagious disease. 12,13 Use antimicrobials effectively and implement an antimicrobial stewardship program in your facillity. 12,13 Optimize dosing and duration of treatment. 4 Follow treatment guidelines when appropriate. The Public Health Agency of Canada has additional guidelines. These guidelines are for patients identified as colonized or infected with NDM-1 or other carbapenem-resistant gramnegative bacilli within 48 hours of hospital admission. These are intended to prevent and control the spread of resistant organisms: 7,12 1. Clinical screening of all roommates. 2. Six to 12 month review of patient s labs. This is to determine in-hospital presence of organism prior to patient s identification of infection. 3. Consult infection control, microbiology, and public health officials if two or more patients in same organization are infected with or carrying the same organism strain. Consider active culture surveillance on other patients who may have been in contact with these patients.
4 (PL Detail-Document #270713: Page 4 of 5) 4. Environmental sampling should only be done if there is a major outbreak. Routine sampling of family and staff is not indicated. Conclusion Gram-negative bacterial resistance is becoming more common and is difficult to treat. Identify patients at risk and begin appropriate therapy. Reducing health care-associated infections is just as important as appropriately treating patients. Use antimicrobials judiciously and be aware of local antibiogram and resistance data. Wash your hands frequently, place patients in isolation, and prevent cross-contamination. These simple steps will help prevent the spread of infection. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication. Levels of Evidence In accordance with the trend towards Evidence-Based Medicine, we are citing the LEVEL OF EVIDENCE for the statements we publish. Level Definition A High-quality randomized controlled trial (RCT) High-quality meta-analysis (quantitative systematic review) B Nonrandomized clinical trial Nonquantitative systematic review Lower quality RCT Clinical cohort study Case-control study Historical control Epidemiologic study C Consensus Expert opinion D Anecdotal evidence In vitro or animal study Adapted from Siwek J, et al. How to write an evidence-based clinical review article. Am Fam Physician 2002;65: Project Leader in preparation of this PL Detail- Document: Tammie Armeni, RPh, Pharm.D., Assistant Editor Special Expert Contributor: Robert E. Bickerton, MD, FACP References 1. Giamarellou H, Poulakou G. Multi-drug resistant gram-negative infections: what are the treatment options? Drugs 2009;69: Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gramnegative organisms: extended-spectrum betalactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86: Ambrose PG, Owens RC. New antibiotics in pulmonary and critical care medicine. Semin Respir Crit Care Med 2000;21: Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011;27: Struelens MJ, Monnet DL, Magiorakos AP, et al. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010;15(46):pii= Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad spectrum beta-lactamase resistance due to NDM-1herald the end of the antibiotic era for treatment of infections caused by gram-negative bacteria? J Antimicrob Chemother 2011;66: Pillai DR, McGeer A, Low DE. New Delhi metallobeta-lactamase-1 in Enterobacteriaceae: emerging resistance. CMAJ 2011;183: CDC. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase United States, MMWR Morb Mortal Wkly Rep 2010;59: Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10: Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008;24: Nation RL, Li J. Colistin in the 21 st century. Curr Opin Infect Dis 2009;22: Public Health Agency of Canada. Guidance: infection prevention and control measures for healthcare workers in all healthcare settings: carbapenem-resistant gram-negative bacilli. Ottawa (ON): The Agency, (Accessed May 4, 2011). 13. CDC. Healthcare-associated infections (HAIs). April 29, (Accessed May 7, 2011).
5 (PL Detail-Document #270713: Page 5 of 5) Cite this document as follows: PL Detail-Document, Resistant Gram-negative Bacteria. Pharmacist s Letter/Prescriber s Letter. July Evidence and Recommendations You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA ~ TEL (209) ~ FAX (209) Subscribers to the Letter can get Detail-Documents, like this one, on any topic covered in any issue by going to or
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationInfection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention
Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationCarbapenemase-Producing Enterobacteriaceae (CPE)
Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationHospital ID: 831. Bourguiba Hospital. Tertiary hospital
Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationPrevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae
Prevention, Management, and Reporting of Carbapenem-Resistant Enterobacteriaceae Dawn Terashita MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health September 28, 2017
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationCarbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationPreserve the Power of Antibiotics
PROVIDERInsight News for providers in Northeast Nebraska April 2016 Preserve the Power of Antibiotics Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce
More informationPreventing and Responding to Antibiotic Resistant Infections in New Hampshire
Preventing and Responding to Antibiotic Resistant Infections in New Hampshire Benjamin P. Chan, MD, MPH NH Dept. of Health & Human Services Division of Public Health Services May 23, 2017 To bring a greater
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationTestimony of the Natural Resources Defense Council on Senate Bill 785
Testimony of the Natural Resources Defense Council on Senate Bill 785 Senate Committee on Healthcare March 16, 2017 Position: Support with -1 amendments I thank you for the opportunity to address the senate
More informationAPIC CHAPTER PRESENTATION 7/2014
2014 CRE THE SUPER BUG - WHY ALL THE BUZZ? Susan Burns BS, MT, CIC, VA-BC Medical Science Liaison DISCLOSURE I am a paid employee of the clinical team of PDI Healthcare. The content of this presentation
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationHand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection.
1. Hand Hygiene Quick Reference Chart Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection. WHEN Before: Direct
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationUsing Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and
Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Health-Care Associated Infections Overall Goals & Objectives:
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationEDUCATIONAL COMMENTARY THE RISE OF CARBAPENEM-RESISTANT ENTEROBACTERIACEAE
ENTEROBACTERIACEAE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationImplementing Antibiotic Stewardship in Rural and Critical Access Hospitals
National Center for Emerging and Zoonotic Infectious Diseases Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals Denise Cardo, MD Director, Division of Healthcare Quality Promotion,
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationInternational Journal of Pharma and Bio Sciences ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACILLI * PRABHAKAR C MAILAPUR, DEEPA
More informationThe threat of multidrug-resistant microorganisms and how to deal with it in Europe
The threat of multidrug-resistant microorganisms and how to deal with it in Europe Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial resistance and Healthcare-associated infections
More informationInfection Prevention and Control Policy
Infection Prevention and Control Policy Control of Multi-Drug-Resistant Gram-Negative Bacilli N.B. Staff should be discouraged from printing this document. This is to avoid the risk of out of date printed
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationDr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,
Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1
More information